Fondazione Luigi Maria Monti — Clinical Trial Site

27 Registered trials

7 Currently recruiting

Organisation

Fondazione Luigi Maria Monti

Location

Rome, Italy

Identifier

ORG-100021341

Address

Roma, Via Dei Monti Di Creta 104, 00167, Italy

Departments

#93133014: UOC Oncologia e Oncologia Dermatologica
#98333014:UO Oncologia
Ambulatorio Malattie Rare
Clinical Dermatology
DERMATOLOGIA
Dermatologia Clinica
Dermatological Clinic
Divisione di Oncologia
I Divisione Dermatologia
Oncologia
Oncologia, Linfedema/Flebo-linfedema
Oncology
Oncology & dermato- oncology
Oncology and Dermato-Oncology
Rare Disease Center
U.O. Ambulatorio di Idrosadenite Suppurativa
Unità di Chirurgia Vascolare

Clinical trials at this site (27)

Search interface

A phase 2 multi-center study investigating the efficacy, safety and tolerability of pioglitazone in adult participants with non-segmental vi… Not authorised

2024-515642-17-00 non-segmental vitiligo 4
NEurotrophins Mimetic compound for the treatment of diabetic foot UlcerS Pending

2024-519405-35-00 Diabetic Foot Ulcer 7
“A phase 2 multi-center study investigating the efficacy, safety and tolerability of pioglitazone in adult participants with non-segmental v… Pending

2025-523266-24-00 Vitiligo 4
Zasocitinib in Nonsegmental Vitiligo Recruiting

2025-522309-40-00 Non-segmental vitiligo 4 2026-02-11
A RANDOMIZED, OPEN-LABEL PHASE 3 STUDY IN PATIENTS WITH PREVIOUSLY TREATED UNRESECTABLE OR METASTATIC NRAS MUTANT CUTANEOUS MELANOMA COMPARI… Recruiting

2024-511404-17-00 Unresectable or metastatic NRAS mutant cutaneous melano 5 2024-10-07
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the E… Recruiting

2023-507039-39-00 Moderate to Severe Plaque Psoriasis 5 2024-03-22
Brivekimig for the treatment of moderate to severe hidradenitis suppurativa Recruiting

2025-522333-61-00 Hidradenitis suppurativa 4 2026-01-23
A Randomized, Double-blind, Vehicle-controlled Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of Topically Applied TCP-25 in P… Recruiting

2024-515172-12-00 Epidermolysis Bullosa 4 2025-12-23
A study to evaluate the efficacy and safety of ruxolitinib cream in children (6 to <12 years old) with non-segmental vitiligo Recruiting

2024-513171-41-00 Vitiligo 5 2025-09-11
An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study with Open-Label Extension Evalu… Recruiting

2023-508818-42-00 Generalized Epidermolysis Bullosa Simplex (EBS) 10 2024-05-21
Study aimed at testing the activity of a course of chemo-immunotherapy with retifanlimab combined with platinum-etoposide followed by surger… Ended

2024-516316-13-00 Merkel cell carcinoma without metastases in other organ 4 2025-01-21
A Clinical Study in which patients with acne vulgaris will receive a new topical drug. The safety and efficacy of the drug will be tested. Ended

2023-510341-19-00 acne vulgaris 5 2024-11-14
A Clinical Study in which patients with acne vulgaris will receive a new topical drug for long term. The safety and efficacy of the drug wil… Ended

2023-510342-24-00 Acne vulgaris 5 2024-11-11
A Study to Evaluate ABP 206 Compared with OPDIVO® (Nivolumab) in Subjects with Unresectable or Metastatic Melanoma Ended

2023-503288-40-00 Unresectable or Metastatic Melanoma 5 2024-01-26
A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination with Pembrolizumab, TransCon TLR7/8 Agonist, or … Ended

2023-509143-27-00 Locally advanced or metastatic solid tumor malignancies 7 2023-11-27
A trial to see if the combination of fianlimab with cemiplimab works better than pembrolizumab for preventing or delaying melanoma from com… Ended

2022-501576-25-00 Melanoma 5 2023-07-07
Clinical Study of Fianlimab in Combination With Cemiplimab versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated U… Ended

2023-505772-30-00 Melanoma 5 2022-11-09
A study in patients with skin cancer Ended

2024-516914-39-00 Metastatic or unresectable melanoma 5 2022-04-27
Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High-risk Stage II Melanoma Ended

2022-501966-23-00 Resected High-Risk Stage II Melanoma 5 2018-09-11
Integrated PK/efficacy, safety, and immunogenicity study to demonstrate similarity of JPB898, a proposed biosimilar to nivolumab, to Opdivo®… Ended

2023-507865-24-00 Advanced (unresectable/metastatic) melanoma 5 2025-03-28
A study to test long-term treatment with spesolimab in people with a skin condition disease called hidradenitis suppurativa (HS) who took pa… Ended

2023-508377-82-00 Hidradenitis Suppurativa (HS) 10 2024-06-27
A study to test whether spesolimab helps people with a skin disease called hidradenitis suppurativa Ended

2022-501074-19-00 Hidradenitis suppurativa 10 2023-10-13
A Study Evaluating Pharmacokinetic Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Stage III and Stage IV … Ended

2022-502620-49-00 Resected Melanoma Stage III or Stage IV 2 2023-08-01
A study to test whether spesolimab helps people with skin disease called Netherton syndrome Ended

2022-501104-10-00 Netherton syndrome (NS) 10 2023-06-06